Please login to the form below

Not currently logged in
Email:
Password:

Entyvio

This page shows the latest Entyvio news and features for those working in and with pharma, biotech and healthcare.

Immunology keeps Shire figures solid as Takeda takeover nears

Immunology keeps Shire figures solid as Takeda takeover nears

There were gains for newer products Entyvio (vedolizumab) or ulcerative colitis, up a third to around $550m, and myeloma therapy Ninlaro (ixazomib) which climbed 43% to $125m, but Takeda is predicting

Latest news

More from news
Approximately 5 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • Forging a path in specialty care Forging a path in specialty care

    Adcetris (for Hodgkin Lymphoma), Entyvio (for ulcerative colitis and Crohn's Disease) and future compound Ninlaro (an oral protease inhibitor for relapsed/refractory multiple myeloma) which was approved by the FDA ... The best example is Entyvio. It

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics